17768217. TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
Contents
- 1 TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
Organization Name
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s)
Tobias Deuse of Burlingame CA (US)
TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION - A simplified explanation of the abstract
This abstract first appeared for US patent application 17768217 titled 'TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
Simplified Explanation
The invention provides cells with enhanced CD16, CD32, or CD64 expression to evade ADCC or CDC.
- Cells with enhanced CD16, CD32, or CD64 expression
- Pluripotent cells, including HIP or HIPO− cells, with enhanced expression
- Cells derived from the pluripotent cells
Potential Applications
The technology could be used in cancer immunotherapy, organ transplantation, and autoimmune disease treatment.
Problems Solved
The technology addresses the issue of immune rejection in cell-based therapies and organ transplantation.
Benefits
Enhanced cell survival and function, improved therapeutic outcomes, and reduced risk of immune rejection.
Potential Commercial Applications
The technology could be applied in biotechnology companies, pharmaceutical companies, and research institutions for developing novel cell-based therapies.
Possible Prior Art
There is no known prior art for cells with enhanced CD16, CD32, or CD64 expression to evade ADCC or CDC.
Unanswered Questions
How scalable is the production of these enhanced cells for clinical applications?
The article does not provide information on the scalability of producing these enhanced cells for large-scale clinical use.
What are the potential side effects or risks associated with using these enhanced cells in therapy?
The article does not discuss any potential side effects or risks that may be associated with using these enhanced cells in therapeutic applications.
Original Abstract Submitted
The invention provides, for the first time, cells that comprise enhanced CD16, CD32, or CD64 expression to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO−), that further comprise the enhanced CD16, CD32, or CD64 expression. The invention encompasses cells derived from the pluripotent cells.
